Coronado is a biopharmaceutical company focused on novel immunotherapy biologic agents for autoimmune diseases and cancer. Coronado's two principal pharmaceutical product candidates are initially targeted for clinical development for inflammatory bowel disease, multiple sclerosis and acute myeloid leukemia.

DEVELOPMENT PIPELINE

TSO

TSO (Trichuris suis ova or CNDO-201) is a biologic for the treatment of autoimmune diseases, such as Crohn's disease, ulcerative colitis and multiple sclerosis.

CNDO-109

CNDO-109 is a biologic that activates natural killer (NK) cells for the treatment of acute myeloid leukemia (AML) and solid tumors.

 

ONGOING CLINICAL TRIALS

Click here for more clinical trial information.